Actively Recruiting
Led by McGill University Health Centre/Research Institute of the McGill University Health Centre · Updated on 2024-03-06
400
Participants Needed
2
Research Sites
52 weeks
Total Duration
M
McGill University Health Centre/Research Institute of the McGill University Health Centre
Lead Sponsor
C
Centre hospitalier de l'Université de Montréal (CHUM)
Collaborating Sponsor
Researchers are conducting a master research protocol to adapt and evaluate the MARVIN chatbot, an artificial intelligence-based conversational agent, for providing information across different health conditions such as HIV infections, breast cancer, and pediatric infectious conditions. This study uses an adaptive platform trial design to allow multiple chatbot interventions tailored to various populations, enabling early withdrawal of ineffective arms and introduction of new ones. The goal is to develop, adapt, and assess the usability and implementation outcomes of these chatbots through co-construction with participants and research teams. The study involves four chatbot interventions delivered via Meta (Facebook) Messenger: MARVIN for HIV patients, MARVIN-Pharma for community pharmacists, MARVINA for breast cancer patients, and MARVIN-CHAMP for pediatric patients with infectious conditions. Participants will be involved in co-constructing the chatbots, usability studies, implementation, evaluation of outcomes, and continuous improvements. This ongoing process allows the chatbots to be progressively refined to meet the needs of each user group. Participants aged 14 and older who understand the study requirements and have access to a smartphone, tablet, or computer with internet or data plan will engage with the chatbots over time. Researchers will assess usability using tools like the Usability Metric for User eXperience (UMUX-Lite) and Acceptability E-Scale (AES) immediately and at intervals over 12 months. They will also evaluate implementation outcomes such as intervention appropriateness and compatibility. Throughout the study, participants' interaction with the chatbots and their experience will be continuously monitored and improved.
CONDITIONS
The MARVIN Chatbots to Provide Information for Different Health Conditions
You may qualify if you...
You will not qualify if you...
Complete this quick 3-step screening to check your eligibility
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person or remote) to confirm eligibility and provide informed consent
Duration - 1 month
Participants collaborate in adapting the chatbot and evaluate its usability in their specific healthcare context.
Initial baseline visit followed by usage over 1 month with remote check-ins
Duration - Up to 12 months
Participants use the chatbot over time while researchers evaluate implementation fidelity and user outcomes such as acceptability and appropriateness.
Quarterly visits (every 3 months) for assessments over 12 months
Total: 2 locations
1
Centre hospitalier de l'Université de Montréal (CHUM)
Montreal, Quebec, Canada, H2X 3E4
Actively Recruiting
2
McGill University Health Centre (MUHC)
Montreal, Quebec, Canada, H4A 3J1
Actively Recruiting
B
Bertrand Lebouché, MD
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
OTHER
Number of Arms
4
Have more questions? Get in touch with our team for quick support
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Yuanchao Ma, Sofiane Achiche, Marie-Pascale Pomey...
https://pubmed.ncbi.nlm.nih.gov/38349734